arrow
C

Chung Hyo Kang

university of science & technology (ust)
H指数:9
被引数:433

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R

用脂肪胺替换色瑞替尼中的末端哌啶可赋予针对克唑替尼耐药突变体的活性,包括G1202R

2017-01-0115
PREAI